[EN] IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE CXCR4
申请人:UNIV PARIS
公开号:WO2020201096A1
公开(公告)日:2020-10-08
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.
[EN] CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'ISOTHIO-URÉE CYCLIQUES UTILISÉS COMME MODULATEURS DU CXCR4
申请人:ERMIUM THERAPEUTICS
公开号:WO2022064075A1
公开(公告)日:2022-03-31
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.
SYNTHESIS OF IMIDAZOLE 2-THIONES VIA THIOHYDANTOINS
申请人:Garst E. Michael
公开号:US20070203344A1
公开(公告)日:2007-08-30
The present invention provides a method of making an imidazole 2-thione which comprises the step(s) of reducing a thiohydantoin to said imidazole-2-thione.
本发明提供了一种制备咪唑-2-硫酮的方法,其包括将硫代异噁唑酮还原为所述的咪唑-2-硫酮的步骤。
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups
New histamine H-3-receptor antagonists were synthesised and tested on rat brain membranes and on electrically stimulated guinea-pig ileum. The new compounds have a central polar group represented by a 2-alkylimidazole or a 2-thioimidazoline nucleus. The effect of the polar group basicity on the optimal length of the alkyl chain, connecting this group to a 4(5)-imidazolyl ring, was investigated. The best affinity values, obtained by displacement of [H-3]-RAMHA from rat brain, were obtained for the 2-alkylimidazole derivatives (2a-f) with tetramethylene chain (pK(i) 8.03-8.97), having an intermediate basicity between that of the previously reported 2-thioimidazoles (1a-i) and that of 2-alkylthioimidazolines (3a-h). In contrast, a general lowering of affinity (pK(i) 5.90-7.63) was observed for compounds of the last series (3a-h), with a complex dependence on the terminal lipophilic group and chain length. (C) 2000 Elsevier Science S.A. All rights reserved.